News for Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics (NTLA) awarded 23,800 RSUs to six new employees under its 2024 Inducement Plan. The RSUs are set to vest in three equal installmen

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.

On July 1, 2025, Eliana Clark, Executive Vice President and Chief Technical Officer at Intellia Therapeutics Inc, sold 1,022 shares of the company. Following th

On July 1, 2025, Jesse Goodman, a Director at Intellia Therapeutics Inc (NTLA), sold 3,094 shares of the company. Following this transaction, the insider now ow

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 patients were free of attacks and treatment for a median […]

On June 16, 2025, HC Wainwright & Co., a well-regarded financial services company, reiterated its "Buy" rating for Intellia Therapeutics (NTLA). The decision to

Intellia Therapeutics (NTLA) announces 98% reduction in monthly HAE attacks from a single dose of lonvoguran ziclumeran. All 10 patients in Phase 1 tria

On June 3, 2025, Canaccord Genuity analyst Whitney Ijem has maintained a 'Buy' rating for Intellia Therapeutics (NTLA). However, there is a noteworthy adjustmen

Intellia Therapeutics (NTLA) has experienced a reduction in its price target from $74 to $54 by Canaccord, although the firm maintained its Buy rating on the st

ARK Investment Management, led by Cathie Wood, has expanded its stake in Intellia Therapeutics (NTLA) by purchasing 226,000 shares. This move underscores ARK's

ARK Investment Management, led by Cathie Wood, has recently expanded its holdings by purchasing 201,000 shares of Intellia Therapeutics (NTLA). This strategic a

Market Overview NVIDIA (NVDA) gained attention through strong quarterly results and positive guidance, pushing its stock up by 3.2%. Market focus shifte

Intellia Therapeutics (NTLA) disclosed a significant safety incident related to grade 4 liver transaminase elevation in its Phase 3 MAGNITUDE study. This develo

Key Takeaways: Intellia Therapeutics (NTLA) faces a challenge in its Phase 3 trial but remains committed to its long-term goals. Analysts see significant

Intellia Therapeutics (NTLA) reported a significant development in its Magnitude trial for transthyretin amyloid cardiomyopathy, revealing the first instance of

U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Thursday. Shares of HP Inc. HPQ fell sharply in today's pre-mark...

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Florida-based Zeo Energy Corp. (ZEO) is up over 121 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Shares of NVIDIA Corporation NVDA rose sharply in today's pre-market trading after the company posted first-quarter results. The company reported first-quarter...